search
Back to results

FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues

Primary Purpose

Colorectal Cancer, Monkey Pox

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Immunohistochemical staining with anti-FOS
Sponsored by
xiaoliang Huang
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Cancer focused on measuring Differential expression of gene, Immunohistochemical staining, Tumor microenvironment

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: (a) patients with histologically confirmed CRC (b) patients who underwent resection of the primary tumor (c) patients at first visit who had not received treatment before blood testing. Exclusion Criteria: (a) familial adenomatous polyposis or hereditary colon cancer (b) no signs of clinical infection, such as fever, on the day of blood collection; And (c) patients with multiple primary tumors during hospitalization.

Sites / Locations

  • Guangxi Medical University Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Test group-stained by FOS antibody

Arm Description

Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.

Outcomes

Primary Outcome Measures

Original survival
Time from the start of the study to death from any cause. For subjects who were lost to follow-up before death, the time of last follow-up was calculated as the time of death.

Secondary Outcome Measures

Full Information

First Posted
January 16, 2023
Last Updated
January 25, 2023
Sponsor
xiaoliang Huang
search

1. Study Identification

Unique Protocol Identification Number
NCT05698082
Brief Title
FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues
Official Title
Monkeypox and Cancer: a Pan-cancer Based Multi-omics Analysis and Single Cell Sequencing Analysis-Experimental Studies
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
xiaoliang Huang

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Colorectal cancer tissue sections were obtained according to the inclusion criteria. The formalin was used to immersed all cancer specimens. And tissues were cut to 5 μm thickness and placed on glass slides before staining. Endogenous peroxidase activity was inhibited and blocked by de-paraffinizing, rehydrating, and using 5% bovine serum albumin at 37ºC for 30 min. The treated sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Monkey Pox
Keywords
Differential expression of gene, Immunohistochemical staining, Tumor microenvironment

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Test group-stained by FOS antibody
Arm Type
Experimental
Arm Description
Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.
Intervention Type
Diagnostic Test
Intervention Name(s)
Immunohistochemical staining with anti-FOS
Intervention Description
The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
Primary Outcome Measure Information:
Title
Original survival
Description
Time from the start of the study to death from any cause. For subjects who were lost to follow-up before death, the time of last follow-up was calculated as the time of death.
Time Frame
Participants were followed up for 3 years, including outpatient follow-up and telephone follow-up.

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (a) patients with histologically confirmed CRC (b) patients who underwent resection of the primary tumor (c) patients at first visit who had not received treatment before blood testing. Exclusion Criteria: (a) familial adenomatous polyposis or hereditary colon cancer (b) no signs of clinical infection, such as fever, on the day of blood collection; And (c) patients with multiple primary tumors during hospitalization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaoliang Huang, Dr.
Phone
0086-13617713823
Email
xiaoliang@sr.gxmu.edu.cn
Facility Information:
Facility Name
Guangxi Medical University Cancer Hospital
City
Nanning
State/Province
Guangxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiangliang Huang, Dr.
Phone
+8613617713823
Email
xiaoliang@sr.gxmu.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues

We'll reach out to this number within 24 hrs